In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target of $170.00. The company’s shares closed last Friday at $79.51.
According to TipRanks, Arce is a 4-star analyst with an average return of 10.0% and a 40.16% success rate. Arce covers the Healthcare sector, focusing on stocks such as Akebia Therapeutics, Assembly Biosciences, and Pliant Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Madrigal Pharmaceuticals with a $150.00 average price target, which is an 88.66% upside from current levels. In a report released on August 4, JMP Securities also reiterated a Buy rating on the stock with a $180.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $105.93 and a one-year low of $52.33. Currently, Madrigal Pharmaceuticals has an average volume of 188.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Read More on MDGL:
- H.C. Wainwright Keeps Their Hold Rating on Galmed Pharmaceuticals (GLMD)
- Benchmark Co. Reaffirms Their Hold Rating on Western Digital (WDC)
- Needham Remains a Buy on Revolve Group (RVLV)
- Wall Street Analysts Are Neutral on Top Healthcare Picks
- RADA Schedules Second Quarter 2022 Results Release & Conference Call on Wednesday, August 17, 2022
